Free Trial

Adaptimmune Therapeutics Q4 2024 Earnings Report

Adaptimmune Therapeutics logo
$0.20 -0.01 (-3.40%)
As of 01:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Adaptimmune Therapeutics Revenue Results

Actual Revenue
$3.22 million
Expected Revenue
$16.56 million
Beat/Miss
Missed by -$13.34 million
YoY Revenue Growth
N/A

Adaptimmune Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Adaptimmune Therapeutics Earnings Headlines

Analysts Offer Predictions for ADAP Q1 Earnings
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Barclays Remains a Sell on Adaptimmune Therapeutics (ADAP)
Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
See More Adaptimmune Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptimmune Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your email.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics (NASDAQ:ADAP), a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

View Adaptimmune Therapeutics Profile

More Earnings Resources from MarketBeat